CMPS
COMPASS PathwaysDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Positive late-stage readouts, constructive FDA interactions, and payer traction could re-rate COMPASS toward analyst upside within 12 months.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.4.
What can break
Binary clinical trial/readout failure
Momentum
90
Value
41
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.17 · Bull $16.08 · Bear $5.48
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $23.44
Why
Momentum90 · Δ7d -1.4
Value41 · Δ7d +0.0
Sentiment24 · Δ7d +5.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendFlat
Δ7d
-1.4
Δ21d
-6.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
24
34% active weight
Current posture
7d trendImproving
Δ7d
+5.0
Δ21d
+10.5
Why this grade
Composite grade D. Momentum 90.1 / Value 41.1 / Sentiment 24.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.57B
Beta
1.93
Shares Out
134.92M
P/E (TTM) · Derived
-3.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.50
Rev YoY
-
EPS YoY
+51.4%
Gross Margin
-
Op Margin
-
Net Debt
-$114.95M
Current Ratio
3.32
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology